Kirkland Advises Eli Lilly on $1.4 Billion Acquisition of POINT Biopharma

Advising firms

The announcement does not name individual lawyers.

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value

USD 1.40bn ($1.4 billion)

What the figure measures

Total transaction value

Client

Eli Lilly and CompanyBuy-side

Counterparties

POINT Biopharma Global Inc. (Sell-side)